➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: August 15, 2020

DrugPatentWatch Database Preview


➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Oxcarbazepine patents expire, and what generic alternatives are available?

Oxcarbazepine is a drug marketed by Amneal Pharms, Hikma, Sun Pharm Inds Ltd, Ani Pharms Inc, Breckenridge Pharm, Glenmark Pharms Ltd, Jubilant Cadista, Rubicon, Sun Pharm Inds, and Taro. and is included in eleven NDAs.

The generic ingredient in OXCARBAZEPINE is oxcarbazepine. There are twenty-one drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the oxcarbazepine profile page.

US ANDA Litigation and Generic Entry Outlook for Oxcarbazepine

A generic version of OXCARBAZEPINE was approved as oxcarbazepine by GLENMARK PHARMS LTD on October 9th, 2007.

  Start Trial

Drug patent expirations by year for OXCARBAZEPINE

See drug prices for OXCARBAZEPINE

Drug Sales Revenue Trends for OXCARBAZEPINE

See drug sales revenues for OXCARBAZEPINE

Recent Clinical Trials for OXCARBAZEPINE

Identify potential brand extensions & 505(b)(2) entrants

Weill Medical College of Cornell UniversityPhase 4
Eisai Inc.Phase 4
UCB Biopharma S.P.R.L.Phase 1

See all OXCARBAZEPINE clinical trials

Pharmacology for OXCARBAZEPINE
Paragraph IV (Patent) Challenges for OXCARBAZEPINE
Tradename Dosage Ingredient NDA Submissiondate
OXTELLAR XR TABLET, EXTENDED RELEASE;ORAL oxcarbazepine 202810 2013-04-12
OXTELLAR XR TABLET, EXTENDED RELEASE;ORAL oxcarbazepine 202810 2013-03-20
TRILEPTAL SUSPENSION;ORAL oxcarbazepine 021285 2006-12-26
TRILEPTAL TABLET;ORAL oxcarbazepine 021014 2006-05-05

US Patents and Regulatory Information for OXCARBAZEPINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Amneal Pharms OXCARBAZEPINE oxcarbazepine SUSPENSION;ORAL 202961-001 Sep 17, 2012 AB RX No No   Start Trial   Start Trial   Start Trial
Jubilant Cadista OXCARBAZEPINE oxcarbazepine TABLET;ORAL 090239-003 Jan 25, 2010 DISCN No No   Start Trial   Start Trial   Start Trial
Sun Pharm Inds OXCARBAZEPINE oxcarbazepine TABLET;ORAL 077794-003 Oct 9, 2007 AB RX No No   Start Trial   Start Trial   Start Trial
Breckenridge Pharm OXCARBAZEPINE oxcarbazepine TABLET;ORAL 078069-001 Jan 11, 2008 AB RX No No   Start Trial   Start Trial   Start Trial
Ani Pharms Inc OXCARBAZEPINE oxcarbazepine TABLET;ORAL 078005-001 Dec 11, 2007 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.